Alnylam Pharmaceuticals Inc (ALNY)

70.74
0.82 1.10
NASDAQ : Health Care
Prev Close 71.56
Open 71.32
Day Low/High 70.28 / 73.28
52 Wk Low/High 49.96 / 116.96
Volume 512.90K
Avg Volume 836.80K
Exchange NASDAQ
Shares Outstanding 85.72M
Market Cap 6.07B
EPS -3.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Alnylam To Webcast Presentation At Canaccord Genuity Growth Conference

Alnylam To Webcast Presentation At Canaccord Genuity Growth Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Canaccord Genuity 36 th Annual Growth Conference on...

Perilous Reversal Stock: Alnylam Pharmaceuticals (ALNY)

Perilous Reversal Stock: Alnylam Pharmaceuticals (ALNY)

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a "perilous reversal" (up big yesterday but down big today) candidate

Alnylam To Webcast Conference Call Discussing Second Quarter 2016 Financial Results

Alnylam To Webcast Conference Call Discussing Second Quarter 2016 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter on Thursday, August 4, 2016, after the U.

Alnylam Announces New Positive Interim Phase 1 Study Results For Fitusiran, A Once-Monthly, Subcutaneous, Investigational RNAi Therapeutic Targeting Antithrombin For The Treatment Of Hemophilia And Rare Bleeding Disorders

Alnylam Announces New Positive Interim Phase 1 Study Results For Fitusiran, A Once-Monthly, Subcutaneous, Investigational RNAi Therapeutic Targeting Antithrombin For The Treatment Of Hemophilia And Rare Bleeding Disorders

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today new positive results from its ongoing Phase 1 study with fitusiran, an investigational RNAi therapeutic targeting...

Today's Weak On High Volume Stock: Alnylam Pharmaceuticals (ALNY)

Today's Weak On High Volume Stock: Alnylam Pharmaceuticals (ALNY)

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a weak on high relative volume candidate

Alnylam To Report New Clinical Results With Fitusiran At The World Federation Of Hemophilia (WFH) 2016 World Congress

Alnylam To Report New Clinical Results With Fitusiran At The World Federation Of Hemophilia (WFH) 2016 World Congress

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that Alnylam and collaborators will present interim results from the ongoing Phase 1 clinical trial with fitusiran,...

5 Toxic Stocks to Sell as Anxiety Creeps Higher

5 Toxic Stocks to Sell as Anxiety Creeps Higher

It's time to unload these toxic stocks from your portfolio.

Alnylam To Host Third Annual

Alnylam To Host Third Annual "RNAi Roundtable" Webcast Series

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it plans to host its 3 rd Annual series of webcast "RNAi Roundtables" this summer and early fall.

Alnylam Initiates Phase 1/2 Clinical Trial For ALN-HBV, An Investigational RNAi Therapeutic For The Treatment Of Chronic Hepatitis B Virus Infection

Alnylam Initiates Phase 1/2 Clinical Trial For ALN-HBV, An Investigational RNAi Therapeutic For The Treatment Of Chronic Hepatitis B Virus Infection

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it has initiated a Phase 1/2 clinical trial with ALN-HBV, a subcutaneously administered investigational RNAi...

Barbarian At The Gate: Alnylam Pharmaceuticals (ALNY)

Barbarian At The Gate: Alnylam Pharmaceuticals (ALNY)

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

Alnylam Reports New Results From Investigational RNAi Therapeutic Programs For Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy (hATTR-PN) And Cardiomyopathy (hATTR-CM)

Alnylam Reports New Results From Investigational RNAi Therapeutic Programs For Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy (hATTR-PN) And Cardiomyopathy (hATTR-CM)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today preliminary results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, both...

Alnylam Pharmaceuticals (ALNY) Highlighted As Today's Perilous Reversal Stock

Alnylam Pharmaceuticals (ALNY) Highlighted As Today's Perilous Reversal Stock

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a "perilous reversal" (up big yesterday but down big today) candidate

Alnylam To Report New Patisiran And Revusiran Results At The XV International Symposium On Amyloidosis

Alnylam To Report New Patisiran And Revusiran Results At The XV International Symposium On Amyloidosis

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that Alnylam scientists and collaborators will present preliminary results from its ongoing Phase 2 open-label...

Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan

Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan

Cramer says you may be able to pick up a lot of high-quality stocks cheap this week.

'Mad Money' Lightning Round: Buy, Buy, Buy UnitedHealth Group

'Mad Money' Lightning Round: Buy, Buy, Buy UnitedHealth Group

Cramer is interested in Monster Beverage and is avoiding Oasis Petroleum.

Alnylam Reports Initial ALN-CC5 Results In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) From Ongoing Phase 1/2 Study

Alnylam Reports Initial ALN-CC5 Results In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) From Ongoing Phase 1/2 Study

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and collaborators today presented initial results from Part C of its ongoing Phase 1/2 clinical trial with ALN-CC5 - a...

Alnylam Initiates Phase 1 Clinical Trial For ALN-TTRsc02, An Investigational RNAi Therapeutic For The Treatment Of TTR-Mediated Amyloidosis

Alnylam Initiates Phase 1 Clinical Trial For ALN-TTRsc02, An Investigational RNAi Therapeutic For The Treatment Of TTR-Mediated Amyloidosis

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it has initiated a Phase 1 clinical trial with ALN-TTRsc02, a subcutaneously administered investigational RNAi...

Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's

Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a "dead cat bounce" (down big yesterday but up big today) candidate

Stock To Watch: Alnylam Pharmaceuticals (ALNY) In Perilous Reversal

Stock To Watch: Alnylam Pharmaceuticals (ALNY) In Perilous Reversal

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a "perilous reversal" (up big yesterday but down big today) candidate

Alnylam To Webcast Conference Call Discussing ALN-CC5 Phase 1/2 Data

Alnylam To Webcast Conference Call Discussing ALN-CC5 Phase 1/2 Data

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will discuss initial results in patients with paroxysmal nocturnal hemoglobinuria (PNH) from the ongoing...

Alnylam To Webcast Presentations At Upcoming June Investor Conferences

Alnylam To Webcast Presentations At Upcoming June Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Goldman Sachs 37 th...

Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's

Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's "Perilous Reversal" Stock

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a "perilous reversal" (up big yesterday but down big today) candidate

Alnylam Rises After Ionis Partner Decides Not To Start Phase 3 Study

Alnylam Rises After Ionis Partner Decides Not To Start Phase 3 Study

Shares of Ionis Pharmaceuticals plummeted this morning after the company announced that its partner GlaxoSmithKline had decided not to initiate a Phase 3 outcome study that was planned to evaluate...

Strong On High Volume: Alnylam Pharmaceuticals (ALNY)

Strong On High Volume: Alnylam Pharmaceuticals (ALNY)

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a strong on high relative volume candidate

Insiders Now Seeing Red With ALNY At New 52-Week Low

Insiders Now Seeing Red With ALNY At New 52-Week Low

In trading on Thursday, shares of Alnylam Pharmaceuticals Inc touched a new 52-week low of $49.96/share. That's a $90.04 share price drop, or -64.31% decline from the 52-week high of $140.00 set back on 06/23/2015.

Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's Weak On High Relative Volume Stock

Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's Weak On High Relative Volume Stock

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a weak on high relative volume candidate

Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's

Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's "Water-Logged And Getting Wetter" Stock

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate

Alnylam Pharmaceuticals Reports First Quarter 2016 Financial Results And Highlights Recent Period Progress

Alnylam Pharmaceuticals Reports First Quarter 2016 Financial Results And Highlights Recent Period Progress

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter 2016, and highlighted recent progress in advancing its pipeline.